Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age
- 1 March 2012
- journal article
- clinical trial
- Published by Elsevier BV in Vaccine
- Vol. 30 (15), 2556-2563
- https://doi.org/10.1016/j.vaccine.2012.01.087
Abstract
No abstract availableThis publication has 32 references indexed in Scilit:
- Vaccine Adjuvants: Putting Innate Immunity to WorkImmunity, 2010
- Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patientsExpert Opinion on Biological Therapy, 2008
- Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adultsVaccine, 2006
- A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvantVaccine, 1999
- Immune Activation by Bacterial DNA: A New Genetic CodeImmunity, 1996
- Hexamer Palindromic Oligonucleotides with 5′CG-3′ Motif(s) Induce Production of InterferonJournal of Interferon & Cytokine Research, 1996
- Bacterial DNA Induces Murine Interferon-γ Production by Stimulation of Interleukin-12 and Tumor Necrosis Factor-αCellular Immunology, 1996
- CpG motifs in bacterial DNA trigger direct B-cell activationNature, 1995
- Hepatitis-B Vaccination in the ElderlyThe Journal of Infectious Diseases, 1984
- Hepatitis B VaccineThe New England Journal of Medicine, 1980